AliveCor said today that it landed $30 million in a series D funding round and that it released its artificial intelligence-enabled Kardia Pro platform in the U.S.
The company’s platform enables doctors to remotely monitor their patients for early signs of atrial fibrillation, a common cardiac arrhythmia.
“Heart disease is the No. 1 cause of death in the United States, claiming more lives than all forms of cancer combined. To manage heart disease and stroke risk, leading cardiologists want to see more than just ECGs from their patients,” CEO Vic Gundotra said in prepared remarks. “Kardia Pro tracks important measures of physiology like weight, activity and blood pressure, and, for the first time, AI technology is used to create a personal heart profile for each user, enabling user identification. The new platform enables doctors to be better doctors and patients to be more active participants in their own heart health, driving healthcare forward into the 21st century.”
“What I find so compelling about Kardia is how it empowers my patient, making them much more proactive in their own healthcare,” cardiac electrophysiologist Dr. Theodore Takata said. “Reviewing data this quickly also lets me make important medical decisions, accelerating the time to diagnosis and avoiding unnecessary healthcare utilization.”
The series D funding round was led by investments from Omron Healthcare and Mayo Clinic, alongside existing investors. The company said it plans to use the funds to expand its business.
“Omron Healthcare is excited to expand our strategic partnership with AliveCor. We are establishing new partnerships to redefine the role of technology in heart health as part of our Going for Zero mission. Partnering with AliveCor advances our path forward to build robust software programs that play a dynamic role in expanding heart health awareness, transforming the patient and caregiver dynamic and taking real steps toward eliminating heart attack and stroke,” Omron Healthcare president & CEO Ranndy Kellogg said.